Welcome! Whether you are a potential investor in BioCryst Pharmaceuticals or you are already a shareholder, our investor center is the primary source of information about the company. Just choose a topic, or if you have a question, email us.
RESEARCH TRIANGLE PARK, N.C. and EXTON, Pa. , March 22, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. ("BioCryst") (NASDAQ:BCRX), and Idera Pharmaceuticals, Inc. ("Idera") (NASDAQ:IDRA), today announced they will be presenting at the 17 th Annual Needham Healthcare Conference on Tuesday,
RESEARCH TRIANGLE PARK, N.C. , March 15, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today the dosing of the first patient into APeX-2, a Phase 3 clinical trial evaluating two dosage strengths of BCX7353 administered orally once-daily (QD) as a preventive
Questions about stock transfers and lost certificates should be directed to the transfer agent: American Stock Transfer & Trust Company
59 Maiden Lane
New York, NY 10038
1-800-937-5449 (toll free in US and Canada)
1-718-921-8200 (callers outside the US and Canada)